The number 150 used to belong to myth. Ancient emperors sent expeditions in search of immortality elixirs. Medieval explorers mapped coastlines looking for fountains that would stop time. Today, the quest has moved into university genetics labs, Boston biotech startups, and the offices of the U.S. Food and Drug Administration. What was once fantasy is now, at minimum, a serious scientific hypothesis backed by data, institutional funding, and some of the most credentialed researchers on earth.
That shift didn’t happen overnight. It gathered momentum through two decades of discoveries about how cells age, and crucially, whether that process can be slowed or reversed. The answers coming from those labs are not yet settled. The science is early, the human data thin, and some researchers remain deeply skeptical. But the pace of progress has accelerated sharply, and 2025 and early 2026 brought several developments that even cautious observers called milestones.
For anyone paying attention to longevity science, right now is genuinely different from any prior moment. Not because anyone has conquered aging, but because the first clinical trials targeting aging itself are now underway. The question of whether 150 is possible has moved, however tentatively, from philosophy into the domain of testable biology.
What the Data Says: How Long Can Humans Actually Live?
The starting point for any serious discussion of maximum human lifespan is what we already know about the limits of biology, independent of disease. One landmark line of inquiry examined this directly. Rather than looking at what kills people, researchers in a 2021 paper in Nature Communications – a collaboration between the biotech company Gero and Roswell Park Comprehensive Cancer Center in Buffalo – tracked how quickly the human body loses its ability to recover from disruptions. They used data from blood tests and wearable activity monitors drawn from more than half a million people in the United States, the United Kingdom, and Russia. They found that our body’s capacity to restore equilibrium across its systems fades predictably with time, and that even absent any major stressor, this incremental decline sets a maximum human lifespan somewhere between 120 and 150 years.
The study concluded that if the obvious hazards don’t take a life first, this fundamental loss of resilience eventually will. Put plainly: even in an ideal world, the body appears to have a hard limit baked in at the biological level.
That limit has a historical reference point. In 1997, Jeanne Calment – the oldest person on verified record – died in France at the age of 122. Nearly 30 years later, no one has surpassed her. This is relevant context: even with all the advances of modern medicine, the upper boundary of documented human life has barely moved.
Meanwhile, at the population level, U.S. life expectancy at birth reached its highest recorded level ever in 2024, rising to 79 years, according to final death data from the CDC’s National Center for Health Statistics. The increase reflected a decline in deaths from COVID-19, as well as falling mortality from heart disease, cancer, and drug overdoses. Climbing from 79 to 150, however, is not a matter of public health improvements. It would require changing the fundamental biology of how cells age.
The Epigenome: Where the Most Promising Science Lives
What Epigenetic Aging Actually Means
Understanding why longevity researchers are excited requires a short detour into cell biology. Every cell in your body carries the same DNA, but what makes a liver cell different from a neuron is not the genetic code itself. It’s which genes get switched on or off. That system of controls is called the epigenome (literally “above the genome”). Harvard geneticist David Sinclair’s central theory proposes that aging occurs due to the loss of epigenetic information – the patterns of DNA molecular tags that influence gene activity – and that this loss can potentially be restored to a more intact, youthful state.
Scientists still debate what fundamentally causes aging, with at least a dozen recognized “hallmarks.” Sinclair’s lab hypothesizes that there is an underlying cause for all of them: a loss of information, a framework they call the Information Theory of Aging.
The theory has a practical implication that sets it apart from many others: if aging is caused not by irreversible DNA damage but by corrupted information that can be restored, then some degree of age reversal may be biologically possible. As Sinclair put it: “If the cause of aging was because a cell became full of mutations, then age reversal would not be possible. But by showing that we can reverse the aging process, that shows that the system is intact – that there is a backup.”
You can explore more about the biological mechanisms behind why human cells age in this overview of human lifespan limits.
From Mouse Eyes to Human Trials
The evidence supporting this theory began in animal models. Sinclair and his team demonstrated the concept by using Yamanaka factor genes – proteins discovered by Nobel laureate Shinya Yamanaka that can reprogram adult cells – to rejuvenate neurons in aged mice, leading to restored vision. The technique also extended the lifespan of mice with a premature aging condition by approximately 40%.
A landmark paper published in the journal Cell in January 2023 pushed the field further. Sinclair and colleagues showed that epigenetic change is a major cause of mammalian aging, and that tweaking the epigenetic information of mice could actively speed up or reverse the effects of aging. That reversibility supports the theory that the primary causes of aging are not mutations in DNA but rather errors in epigenetic instructions.
By 2023, Sinclair’s team had restored vision in aged monkeys, and since those primate studies, the team has been using AI-related techniques to accelerate their research pipeline.
The leap to human testing arrived in January 2026. Life Biosciences, a biotech company co-founded by Sinclair, announced that the FDA had cleared its Investigational New Drug application for a therapy called ER-100. This marked the first-ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials. The gene therapy uses partial epigenetic reprogramming – a technique that modifies chemical tags on DNA to make old cells act younger – with the primary goal of restoring vision in patients with glaucoma and a rarer eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
The company plans to enroll its first patients within a few months, with results potentially available by the end of 2026 or early 2027, according to CEO Jerry McLaughlin. The trial’s primary aim is safety – confirming the therapy can be delivered to human eyes without serious harm. Any improvement in visual function would be considered a signal to progress toward larger efficacy trials.
“This is a huge milestone for the entire partial reprogramming field,” said Yuri Deigin, CEO of rival reprogramming startup YouthBio, noting that the FDA had shown itself “notably open and forward-thinking” in how it engages with this approach.
Senescent Cells: The Other Major Target
Epigenetic reprogramming is not the only scientific avenue attracting serious attention. A parallel field, with arguably more mature clinical data, focuses on what are known as senescent cells. These are cells that have stopped dividing but refuse to die. They continue to exist and release harmful chemicals, contributing to inflammation and tissue damage across the body.
Cellular senescence is a fundamental biological mechanism in which cells permanently exit the cell cycle in response to various stressors. In youth, the immune system clears these cells efficiently. With age, they accumulate, and the damage compounds. Drugs designed to clear them are called senolytics.
Among the most clinically tested senolytic approaches, the combination of Dasatinib (a cancer drug) and Quercetin (a plant flavonoid) stands out as one of the most thoroughly characterized, with extensive use in clinical trials.
Dasatinib plus Quercetin combination has been evaluated in over 15 clinical trials by early 2026, addressing indications including idiopathic pulmonary fibrosis, diabetic kidney disease, Alzheimer’s disease, and frailty.
The field is not without its complications. Throughout clinical development, senolytics have shown concerning off-target effects. Navitoclax, for instance, while effective at clearing senescent cells, causes dose-limiting reductions in platelet counts due to its mechanism of action. Researchers have also observed substantial variation between patients in how they respond to senolytic therapies, partly because cellular senescence is not a uniform process but a context-dependent program influenced by cell type, environment, and age.
The Money Behind the Science
Longevity research has attracted investment at a scale that reflects a serious shift in how the field is perceived. U.S. longevity biotech startups collectively raised more than $3.2 billion in venture capital in 2024, with a substantial portion directed toward senolytic and cellular reprogramming platforms.
Altos Labs, a cellular reprogramming startup backed partly by Amazon founder Jeff Bezos, has secured approximately $5 billion in funding and is reportedly preparing to move toward clinical trials. Retro Biosciences, backed by OpenAI’s Sam Altman, and NewLimit, supported by Coinbase CEO Brian Armstrong, are also pursuing reprogramming-based therapies.
The global anti-aging market generated more than $85 billion in 2025, with projections placing it close to $120 billion by 2030.
The regulatory environment is evolving in parallel. The FDA’s Center for Drug Evaluation and Research issued a draft guidance in Q3 2025 addressing aging as a disease indication, a development that could streamline the approval pathway for longevity therapeutics. Earlier in 2025, the FDA also accepted biological age clocks as secondary endpoints in longevity clinical trials, a pivotal shift for the field’s development and investor confidence.
That said, 2025 was an uneven year for the sector. Unity Biotechnology, one of the most prominent companies founded to commercialize senolytics, shuttered in September after several difficult years, while pharmaceutical giant AbbVie declined to extend its long-term collaboration with Calico Life Sciences, Google’s longevity research subsidiary.
Read More: Signs You’re on Track to Reach 100
The Bet, the Skeptics, and the Honest Limits
Aging biologist Steven Austad was so confident that life expectancy was poised for a rapid rise that he placed a public wager in 2000 that the first person to reach 150 was already alive. That bet – now famous in longevity circles – encapsulates the optimism that drives a certain wing of the research community.
That optimism is not universal. Critics note that Sinclair has a history of championing molecules, including sirtuins and resveratrol, that later failed to produce the results he projected. A 2024 Wall Street Journal report described him as a “reverse-aging guru” whose companies “have not panned out.” Others caution that nearly all the most compelling results come from mouse or primate models, and that translating them to humans at scale remains an enormous, unproven step.
The biological resilience research is also sobering in a different way. Analysis of blood markers and physical activity data suggests that the body’s recovery capacity diverges critically between 120 and 150 years of age – a point of complete loss of resilience from which no intervention is likely to rescue the system. In this reading, 150 isn’t an optimistic ceiling. It is a hard wall.
The number of active aging-focused clinical trials globally surpassed 120 by early 2026, a threefold increase from 2020 levels. Most are early-stage. Results take years to emerge. The gap between a compelling mouse study and an approved human therapy is wide, expensive, and littered with failures from other disease areas. Longevity research is unlikely to be different.
What This Means for You
For most people reading this, the practical implications of longevity science fall into two distinct timeframes. The first is now. The habits that support biological age reduction, including regular exercise, strength training, quality sleep, plant-rich diets, and stress management, remain the most evidence-backed tools available by a wide margin. None of the therapies described in this report are available outside of clinical trials, and most won’t be for years. Acting on what is already proven costs nothing and starts today.
The second timeframe is the decade ahead. The FDA clearance of Life Biosciences’ ER-100 trial is not a cure for aging. It is a safety study for a single gene therapy targeting one set of eye diseases. But it represents a real threshold: for the first time, the cellular reprogramming hypothesis is being tested in a human being under regulatory supervision. If the safety data holds, efficacy trials follow. If those work, the science expands to other tissues and organ systems. The path from here to a broadly available anti-aging therapy is long. But as of 2026, it is a path that exists – and it is being actively traveled.
Whether 150 becomes achievable in the lifetimes of people born today remains genuinely uncertain. What is no longer uncertain is that the scientific community is asking the question in earnest, with real data, real trials, and real money on the table. For now, the best strategy is a familiar one: take care of the biology you have, and keep watching the science.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Avoid These 5 Diseases by 60, and You May Live to 100